NEW YORK, Nov. 18, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PACS Group, Inc. (NYSE: PACS).Shareholders who purchased shares of PACS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacs-group-inc-loss-submission-form/?id=112087&from=4CLASS PERIOD: This lawsuit is on  beh ...

Core Viewpoint - A securities class action lawsuit has been filed against PACS Group, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial performance during the Class Period from April 11, 2024, to November 5, 2024 [1][3]. Group 1: Allegations Against PACS Group - The lawsuit claims that PACS engaged in a scheme to submit false Medicare claims, which accounted for over 100% of its operating and net income from 2020 to 2023 [3]. - It is alleged that PACS billed for thousands of unnecessary respiratory and sensory integration therapies to Medicare [3]. - The company is accused of falsifying documentation related to licensure and staffing, leading to misleading positive statements about its business prospects [3]. Group 2: Legal Process and Participation - Investors in PACS have until January 13, 2025, to seek appointment as lead plaintiff, representing the class in the litigation [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [4]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any recovery from the lawsuit [4].

NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against PACS Group, Inc. (NYSE: PACS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in PACS, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/pacs-group-inc. Investors have until January 13, 2025, to ask the Court to be appointed to lead t ...

Core Viewpoint - Investors in PACS Group, Inc. have until January 13, 2025, to file lead plaintiff applications in a securities class action lawsuit due to alleged failures in disclosing material information related to the company's IPO and subsequent securities transactions [1][2]. Group 1: Lawsuit Details - The lawsuit against PACS Group, Inc. is based on claims that the company and certain executives failed to disclose material information in the Registration Statement and during the Class Period, violating federal securities laws [2]. - The case is identified as Manchin v. PACS Group, Inc., et al., No. 24-cv-8636 [4]. Group 2: Company Performance and Market Reaction - On November 6, 2024, PACS disclosed receiving civil investigative demands from the federal government regarding its reimbursement and referral practices, leading to a postponement of its 3Q 2024 earnings release [3]. - Following this announcement, PACS' share price dropped by $11.45, or 38.76%, closing at $18.09 per share on November 6, 2024, with unusually high trading volume [3]. Group 3: Investor Support and Resources - ClaimsFiler provides a free service for shareholders to recover funds from securities class action settlements, offering resources such as registration for case information, portfolio data uploads, and free case evaluations from legal experts [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of PACS Group Inc. common stock related to its IPO and subsequent securities transactions, alleging misleading statements and fraudulent activities by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to PACS Group Inc. common stock purchased during the IPO on April 11, 2024, and securities bought between April 11, 2024, and November 5, 2024 [1]. - The lawsuit claims that PACS engaged in a scheme to submit false Medicare claims, which allegedly drove over 100% of the company's operating and net income from 2020 to 2023 [5]. - Additional allegations include billing for unnecessary therapies to Medicare and falsifying documentation related to licensure and staffing, leading to materially misleading statements about the company's business and prospects [5]. Group 2: Investor Actions - Investors who purchased PACS common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by January 13, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against PACS Group, Inc. (“PACS Group” or “the Company”) (NYSE: PACS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired PACS Group ...

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired PACS Group, Inc. (“PACS” or the “Company”) (NYSE: PACS) securities between April 11, 2024 and November 5, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the federal secu ...

Core Viewpoint - PACS Group, Inc. is facing legal scrutiny due to allegations of fraudulent practices related to Medicare claims, which have significantly impacted its financial performance and stock value [4][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is investigating potential claims against PACS Group and has set a deadline of January 13, 2025, for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that PACS Group and its executives violated federal securities laws by making false statements and failing to disclose critical information regarding their business practices [4]. Group 2: Allegations of Fraudulent Practices - The allegations include a scheme to submit false Medicare claims that accounted for over 100% of PACS' operating and net income from 2020 to 2023, misleading investors about the company's growth and profitability [4][5]. - Specific fraudulent activities cited include billing for unnecessary therapies and falsifying documentation related to licensure and staffing, which contributed to misleading financial statements [4][5]. Group 3: Financial Impact and Stock Performance - Following the release of a report by Hindenburg Research, PACS Group's stock price fell by $11.93, or 27.78%, closing at $31.01 per share on November 4, 2024 [5]. - On November 6, 2024, the company announced a postponement of its fiscal third quarter earnings release, leading to a further decline in stock price by $11.45, or 38.76%, closing at $18.09 per share [6].

Core Viewpoint - A securities class action lawsuit has been filed against PACS Group, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial performance during its IPO and subsequent period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased PACS common stock during its IPO on April 11, 2024, and securities between April 11, 2024, and November 5, 2024 [1]. - The lead plaintiff deadline for the lawsuit is set for January 13, 2025 [1][4]. Group 2: Allegations Against PACS - The complaint alleges that PACS engaged in fraudulent activities, including submitting false Medicare claims that accounted for over 100% of its operating and net income from 2020 to 2023 [3]. - PACS is accused of billing for unnecessary respiratory and sensory integration therapies to Medicare [3]. - The company allegedly falsified documentation related to licensure and staffing, leading to misleading positive statements about its business prospects [3]. Group 3: Lead Plaintiff Process - Investors can seek to be appointed as lead plaintiffs by January 13, 2025, or choose to remain absent class members [4]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [4].

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired PACS Group, Inc. (NYSE: PACS) (a) common stock in connection with the Company's April 11, 2024 initial public offering ("IPO"), or (b) securities between April 11, 2024 and November 5, 2024. PACS Group, through its subsidiaries, operates senior care facilities, skilled nursing facilities, and assisted living facilities in the United ...